Membrane-shed submicron microparticles (MPs) released following cell activation or apoptosis accumulate in atherosclerotic plaques, where they stimulate endothelial proliferation and neovessel formation. The aim of the study was to assess whether or not MPs isolated from human atherosclerotic plaques contribute to increased endothelial adhesion molecules expression and monocyte recruitment.
In view of these data, we tested the hypothesis that MPs isolated from human atherosclerotic plaques can regulate the inflammatory response of endothelial cells, increasing adhesion of monocytes to endothelium and transendothelial migration.
Methods

Isolation and Characterization of MPs From Human Endarterectomy Specimens and Plasma
This study, approved by our Hospital Review Board, included 62 patients undergoing carotid endarterectomy who gave their informed consent before inclusion (Table 1) . MPs were isolated from human atherosclerotic plaques according to a previously described procedure, which does not generate MPs from healthy human arteries 4 (see the Online Data Supplement, available at http://circres.ahajournals.org). All experiments were performed with pelleted MPs gently resuspended in fresh DMEM and compared with the effects either of DMEM alone or of the supernatant obtained after pelleting MPs from plaque homogenates and filtered successively on 0.22-and 0.1-m membranes to completely eliminate potentially residual MPs. Plaque MPs content averaged 183Ϯ17 annexin V positive (AnnV ϩ ) MPs per g lesion (nϭ62). Flow cytometric analysis of MPs is described in the Online Data Supplement. Unless otherwise stated, experiments using plaque MPs were performed at the concentration of 3000 AnnV ϩ MPs/L for duration of 24 hours.
Circulating MPs were isolated from platelet-free plasma obtained by successive centrifugations of venous blood drawn from the same patients, as reported earlier. 17 Experiments on ICAM-1 expression were performed with pelleted circulating MPs and compared with the effect of platelet-free plasma devoid of MPs (obtained after 20 500g centrifugation and then filtered on 0.22-and 0.1-m filters; vehicle) (see the Online Data Supplement).
Assessment of Adhesion Molecule Expression
Expression of adhesion molecules on human umbilical vein endothelial cells (HUVECs), human coronary artery endothelial cells (HCAECs), and COS-7 cells was determined by flow cytometry. Anti-human E-selectin-phycoerythrin (1 L/test), anti-ICAM-1-phycoerythrin-Cyanin5 (20 L/test) and anti-VCAM-1-phycoerythrin (4 L/test) antibodies, were all provided by BD Pharmingen (San Diego, CA). Details are provided in the Online Data Supplement.
Nonspecific protein synthesis inhibitors (cycloheximide, Sigma, St Louis, MO; actinomycin D, Sigma, St Louis, MO) were used. Inhibitors of the following pathways were also used: PI3-kinase ( in the presence of CaCl 2 (5 mmol/L). Control experiments were performed with the same level of buffer and calcium in the absence of annexin V.
We assessed neutralizing anti-human P-selectin antibody at a concentration of 1 g/mL (R&D Systems; Minneapolis, Minn), anti-human PSGL-1 antibody at a concentration of 50 g/mL (R&D Systems; Minneapolis, MN), and their corresponding isotypic control (respectively IgG 1 , R&D Systems; Minneapolis, MN; and IgM; Sigma, Jerusalem, Israel).
Functional Integration of ICAM-1 in Target Cell Membrane
Confluent COS-7 cells plated in 6-well plates were incubated with MPs, or their vehicle (24 hours), washed, and then exposed to activating mouse anti-ICAM-1 antibody (AbDSerotec, Oxford, UK; 30 minutes) or its corresponding isotypic control. A sheep antimouse antibody (Amersham, GE healthcare) was used for cross-linking (15 minutes; 18 ). COS-7 cells in DMEM supplemented or not with 10% FCS served as positive and negative controls, respectively. Proteins were separated by electrophoresis, transferred onto nitrocellulose membranes (Bio-Rad). Membranes were first exposed to anti-P-ERK (Santa Cruz Biotechnology), and then to secondary antibody. After initial immunodetection, membranes were stripped and reprobed with anti-GAPDH antibody (Chemicon, Millipore, Billerica, MA). Details appear in the Online Data Supplement.
Fluorescent Cell Preparation
Human polymorphonuclear (PMN) and U937 cells (details for isolation and culture are provided in the Online Data Supplement) were labeled with 0.5 mol/L fluorescent dye (CellTracker Orange CMTMR; Molecular Probes; Eugene, OR) as described previously. 19 Briefly, the cells were incubated with the fluorescent dye for 30 
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Cell Adhesion Assay
HUVECs plated in 96-well plates were exposed for 24 hours to DMEM, plaque, or plasma MPs or 20500g supernatant. After washout using RPMI medium 1640, fluorescent U937 cells (5000/ well) or phorbol-12-myristate-13-acetate (PMA)-activated human PMN cells (2000/well) were allowed to adhere to HUVECs for 30 minutes. After 2 additional washouts, adherent monocytic cells were counted using a fluorescence microscope (Zeiss Axio Imager Z1).
In some experiments, HUVECs were exposed to neutralizing antibody targeting ICAM-1 or its corresponding isotypic control (IgG 1 ; 10 g/mL; R&D Systems; Minneapolis, MN) for 1 hour before the U937 cell adhesion protocol. U937 cells were pretreated or not with anti-LFA-1 (lymphocyte function associated antigen-1) antibody (10 g/mL; Bender MedSystems, Vienna, Austria) or its corresponding isotypic control (IgG 1 ) (10 g/mL; R&D Systems; Minneapolis, MN).
Cell Adhesion Assay Under Flow Condition
Confluent HUVECs plated in a parallel plate chamber were exposed to plaque MPs or 20500g supernatant. After 24 hours, the parallel plate chamber was connected to a syringe pump and fluorescent U937 cells (55/L) were infused for 30 minutes at a controlled level of laminar low (1 dyn/cm 2 ) or high (10 dyn/cm 2 ) shear stress. During adhesion, the circuit was placed in a sterile 5% CO 2 incubator set at 37°C. After 2 washouts, adherent monocytic cells were counted under fluorescence microscope (Zeiss Axiovert 200 inverted microscope).
Organ Culture
C57BL/6 mouse left and right carotid arteries were isolated, cannulated at both extremities as described previously. 19 Plaque MPs (3000 AnnV ϩ MPs/L) were injected within the arterial lumen. After 24 hours, fluorescent U937 cells were injected in the lumen and allowed to interact for 30 minutes (5ϫ10 6 cells/mL). Adherent cells were counted under a fluorescence microscope. More details appear in the Online Data Supplement.
Transmigration Assays
Confluent HUVECs from the upper chamber of a transmigration assay were exposed to plaque MPs or 20500g supernatant (see the Online Data Supplement). After 24 hours, the medium of the upper chamber was removed and replaced by a medium containing 10 6 PMA-activated human PMN cells. After 24 hours, transmigrated cells in the lower chamber were numbered by flow cytometry analysis.
Immunofluorescent and Scanning Electron Microscopy Analysis
Details regarding immunofluorescent and electron microscopy analysis appear in the Online Data Supplement. To test the hypothesis of a transfer of ICAM-1 from MPs to endothelial cells, plaque MPs were labeled with a primary mouse antihuman ICAM-1 antibody (unlabeled), washed twice, and incubated with HUVECs (3000 AnnV ϩ MPs/L, corresponding to 30 AnnV ϩ MPs/cell) for 24 hours. After washout, cells were incubated either with a fluorescent goat antimouse secondary antibody and analyzed under fluorescence microscope, or with gold-conjugated goat antimouse secondary antibody and analyzed with a scanning electron microscope.
To analyze the mechanism of interaction of MPs with endothelial cells, plaque MPs were incubated with a fluorescent dye, washed twice, and incubated with HUVECs (3000 AnnV ϩ MPs/L). After 24 hours, HUVECs were incubated with primary mouse antihuman CD31 antibodies and then with donkey antimouse secondary antibodies conjugated to Cyanin5. After two more washouts with PBS, nuclei were stained with DAPI.
Quantitative RT-PCR, Western Blotting, and ELISA
Details appear in the Online Data Supplement.
Statistics
Data are presented as meansϮSEM. Wilcoxon and Mann-Whitney tests were used respectively for paired and independent samples. All tests were 2-sided and used a significance level of 0.05. Data handling and analysis were performed with SPSS 12.0 (SPSS Inc, Chicago, IL).
Results
Endothelial cell exposure to plaque MPs augmented the levels of ICAM-1 in a time-and concentration-dependent manner ( Figure 1 ). However, unlike TNF-␣, plaque MPs did not affect endothelial expression of interleukin-8 mRNA (Online Figure I) , endothelial release of interleukin-6, -8, monocyte chemoattractant protein-1 ( Table 2 ) and endothelial expression of VCAM-1 or E-selectin (Online Table I ).
The effect of plaque MPs on endothelial ICAM-1 levels was already detectable at 30 minutes and was as potent as that induced by TNF-␣ after 4 hours exposure (Pϭ0.47; Figure  1B ). After 24 hours of exposure, plaque MPs increased percentage of ICAM-1 ϩ cells by 3.4-fold when compared with the effect of the vehicle (PϽ0.001; Figure 1B ). This increase in ICAM-1 ϩ cells tended to be more robust for MPs obtained from symptomatic than asymptomatic patients, but did not reach statistical significance (4.8Ϯ0.7 versus 3.9Ϯ0.9% of ICAM-1 ϩ cells, nϭ25 and 24, respectively; Pϭ0. 19) . A similar augmentation in ICAM-1 levels was observed for HAECs following exposure to plaque MPs (3.5Ϯ1.3 versus 0.9Ϯ0.1% of ICAM-1 ϩ HAECs for MP and vehicle treated cells, respectively; nϭ6; Pϭ0.03). The effect of plaque MPs on endothelial ICAM-1 was not observed with circulating MPs obtained from the same patients, indicating that the augmented level of ICAM-1 is specific of MPs isolated from human atherosclerotic plaques (Online Figure II) .
We then sought to evaluate the molecular mechanisms leading to the increase in endothelial ICAM-1 levels following exposure to plaque MPs. Quantitative RT-PCR experiments revealed that, if anything, plaque MPs decreased endothelial ICAM-1 mRNA expression after 6 hours exposure, whereas TNF-␣ significantly increased endothelial ICAM-1 mRNA expression ( Figure 2A ). No effect of plaque MPs on ICAM-1 mRNA expression was also observed after 24 hours exposure (data not shown). The effect of plaque MPs on ICAM-1 levels was not affected by actinomycin D or cycloheximide, whereas these agents significantly reduced ICAM-1 expression induced by TNF-␣ (data not shown). We also investigated pathways known to regulate ICAM-1 synthesis in endothelial cells and observed that inhibitors for PI3-kinase (LY-294002), NFB (pyrrolidine dithiocarbamate), MAPK (PD 98059), and PKC (staurosporine, chelerythrine, and Ro 31-8220) pathways did not modify endothelial levels of ICAM-1 following plaque MPs exposure (data not shown). Collectively, these data suggest that the effect of plaque MPs on endothelial ICAM-1 does not result from either increased mRNA expression or protein synthesis.
Given the rapid increase in ICAM-1 (already detectable at 30 minutes), and the lack of effect of plaque MPs on ICAM-1 mRNA expression and protein synthesis, we tested the hypothesis that ICAM-1 transfers from MPs to endothelial cells. ELISA and Western blot analysis demonstrated the presence of substantial amount of ICAM-1 in plaque MPs ( Figure 2B ), but the absence of significant amounts of VCAM-1 or P-selectin (Online Table II ). Unfortunately, ICAM-1 was only weakly detectable on plaque MPs using flow cytometry analysis (0.4Ϯ0.2% of AnnV ϩ MPs; nϭ22), precluding to the determination of the cellular origin of ICAM-1ϩ MPs in the plaque. No significant difference in ICAM-1 level was detected between MPs from symptomatic and asymptomatic patients (327Ϯ231 and 245Ϯ235 ng/mL respectively; Pϭ0.25; nϭ40). To test the hypothesis that ICAM-1 transfers to endothelial cells, plaque MPs were labeled with a mouse anti-ICAM-1 antibody, washed twice to remove unbound antibody, and exposed to endothelial cells. Control experiments were performed with MP washing supernatant. Addition 24 hours later of a fluorescent antimouse secondary antibody revealed that incubation with ICAM-1tagged MPs resulted in an intense ICAM-1 staining on the endothelial surface, whereas supernatant had no effect (Figure 3A) . In a second set of experiments, the secondary antibody to ICAM-1 was gold-conjugated and scanning electron microscopy analysis confirmed ICAM-1 presence at the endothelial surface ( Figure 3B ). Interestingly, the labeling was mostly observed in smooth areas of the endothelial cell surface. In a third set of experiments, MPs were labeled with the fluorescent dye CellTracker Green BODIPY to further assess the interaction between MPs and endothelial membrane. Confocal microscopy analysis demonstrated that Cell-Tracker labeling colocalized with CD31 staining at the endothelial surface ( Figure 3C ). Furthermore, diffuse but significant CellTracker labeling was observed in the endothelial cytosol, attesting that some plaque MPs had fused with the endothelial membrane and delivered their fluorescent dye inside the cytoplasm ( Figure 3C ). Because plaque MPs are mostly of leukocyte origin, 4 we investigated whether the MP-endothelial interaction depended on P-selectin and PSGL-1. 20 PSGL-1 was detected by flow cytometry analysis on plaque MPs (14Ϯ12 PSLG-1 ϩ MPs/g lesion; nϭ7). However, neutralizing antibodies against PSGL-1 and P-selectin (incubated with MPs and endothelial cells respectively) did not affect endothelial ICAM-1 levels on exposure to MPs (nϭ4; 24 hours; data not shown). As anionic phospholipids such as phosphatidylserine favor spontaneous fusion with cell membranes, 21, 22 we then examined the effect Unlike TNF-␣ (positive control), plaque MPs did not enhance the release of interleukin-6, -8, or monocyte chemoattractant protein-1 (MCP-1) following 24 hours of stimulation of HUVECs (nϭ8). Data are given as meansϮSEM.
of annexin V on ICAM-1 transfer to endothelial cells. 20 Preincubation of plaque MPs with annexin V (in the presence of 5 mmol/L CaCl 2 ) decreased by 69Ϯ21% endothelial ICAM-1 level resulting from plaque MP exposure (nϭ6, Pϭ0.03; Figure 3D ). To test whether the mechanisms of ICAM-1 transfer were specific for endothelial cells, we exposed COS-7 cells, known not to express ICAM-1, 23 with plaque MPs; this resulted in the presence of ICAM-1 antigenic reactivity at the surface of COS-7 cells ( Figure 3E ). We then examined whether or not MP-borne ICAM-1 was functionally integrated in the plasma membrane of COS-7 cells following exposure to plaque MPs (24 hours). An activating anti-ICAM-1 antibody increased ERK1/2 phosphorylation, a known downstream event in ICAM-1 mediated signal transduction 24 in COS-7 cells exposed to plaque MPs, but not to supernatant (vehicle) ( Figure 3F ). Collectively, these data demonstrate that MP-borne ICAM-1 is transferred and functionally integrated in target cell membranes.
We next examined the potential functional consequences of the increased ICAM-1 levels attributable to plaque MPs. Exposure to plaque MPs (24 hours) enhanced in vitro adhesion of fluorescent U937 cells to HUVECs, when compared with DMEM or with MP vehicle-treated HUVECs (Figure 4A and 4B) . Conversely, adhesion of fluorescent U937 cells to HUVECs was neither increased by circulating MPs at a concentration of 1000 AnnV ϩ MPs/L (plasma MPs: 9.1Ϯ0.9; plasma supernatant: 8.1Ϯ0.4 cells/mm 2 ; Pϭ0.176; 24 hours; nϭ7) nor at a concentration of 3000 AnnV ϩ MPs/L (plasma MP: 6.4Ϯ1.7; plasma supernatant: 7.2Ϯ1.8 cells/mm 2 ; Pϭ0.345; 24 hours; nϭ5). Plaque MPs also increased the endothelial adhesion of human peripheral PMN cells (2.8Ϯ0.6 PMN cells/mm 2 ; nϭ30), as compared with DMEM (1.8Ϯ0.2 PMN cells/mm 2 ; nϭ19; Pϭ0.007) and with supernatant-treated HUVECs (1.75Ϯ0.2 PMN cells/ mm 2 ; nϭ30; Pϭ0.002). The increase in endothelial adhesion of PMN cells was more pronounced for MPs obtained from symptomatic than asymptomatic patients ( Figure 4C ). The adhesion of U937 cells was decreased by 58Ϯ3% using an anti-LFA-1 neutralizing antibody, and by 72Ϯ2% when combining anti-LFA-1 with anti-ICAM-1 antibodies ( Figure  4D ). The effect of plaque MPs on monocyte adhesion to endothelial cells persisted under low shear (plaque MP: 4.1Ϯ0.3; supernatant: 3.5Ϯ0.3 cells/mm 2 ; Pϭ0.043; 3000 AnnV ϩ MPs/L; 24 hours; nϭ5) and high shear stress conditions (plaque MP: 2.7Ϯ0.2; supernatant: 2.0Ϯ0.1 cells/ mm 2 ; Pϭ0.018; 3000 AnnV ϩ MPs/L; 24 hours; nϭ7). Monocyte adhesion was also evaluated ex vivo in mouse carotid arteries maintained in organ culture at 80 mm Hg intraluminal pressure and exposed intraluminally to either plaque MPs or vehicle under static conditions for 24 hours. The number of adherent U937 cells was increased by 1.7 fold in vessels exposed plaque MPs, as compared with control conditions (Pϭ0.02; nϭ7) ( Figure 4E ). Exposure of U937 cells to anti-LFA-1 and carotid artery to anti-ICAM-1 neutralizing antibodies decreased U937 cells adhesion to carotid artery by 83Ϯ11% as compared with the corresponding isotypic IgGs controls (nϭ4, Pϭ0.039) (Online Figure III) . Thus, exposure of endothelial cells to plaque MPs favors monocytic cell adhesion both in vitro and ex vivo, under static and under flow conditions. Then, we sought to evaluate whether or not plaque MPs promote endothelial transmigration of PMN cells. Plaque MPs (24 hours) significantly increased PMN transmigration (nϭ16; Pϭ0.013) and this effect was more robust for MPs isolated from symptomatic than asymptomatic patients (140Ϯ34 versus 107Ϯ19% of vehicle effect; nϭ8 each; Pϭ0.04).
Discussion
The present study demonstrates that ICAM-1 can transfer from human plaque MPs to endothelial cells, leading to increased leukocyte adhesion and transmigration. MPs originating from plaques may thus contribute to the progression and development of human atherosclerotic lesions.
We observe here that exposure to MPs isolated from human atherosclerotic plaques rapidly increases ICAM-1 at the endothelial cell surface, despite the lack of endothelial with an anti-ICAM-1 antibody, washed to remove unbound antibody, and incubated with HUVECs for 24 hours (3000 AnnV ϩ MPs/L). Fluorescent secondary antibody was then applied, revealing an intense staining on the surface of endothelial cells incubated with MPs but not with washing supernatant. In the upper panels, nuclei are stained with DAPI (blue) (original magnification, ϫ 40). These images are representative of 5 experiments. In the lower panels, confocal microscopy analysis confirmed the plasma membrane localization of the ICAM-1 staining (original magnification, ϫ 40; representative of 3 experiments). In these experiments, plaque MPs, but not HUVECs, were incubated with the anti-ICAM-1 antibody. This explains why there is no staining for ICAM-1 on endothelial cell treated with "supernatant." B, Plaque MPs were labeled with an anti-ICAM-1 antibody, washed to remove unbound antibody, and incubated with HUVECs for 24 hours (3000 AnnV ϩ MPs/L). Goldconjugated secondary antibody was then applied, revealing by electron microscopy an intense staining on the surface of endothelial cells incubated with MPs but not with washing supernatant. C, Plaque MPs were labeled with the fluorescent CellTracker Green BODIPY dye (green), washed to remove unbound dye, and incubated with HUVECs (3000 AnnV ϩ MPs/L). After 24 hours, fluorescent MPs colocalized with CD31 staining (red, arrow) but cytoplasm was also green (arrowhead), suggesting that at least a part of MPs had fused with cell plasma membrane. In the top images, nuclei are stained with DAPI (blue) (original magnification, ϫ40). These images are representative of 9 experiments. In the bottom images, confocal microscopy analysis confirmed the presence of MPs on the plasma membranes, as demonstrated by the colocalization of CD31 (red) and Cell-tracker labeled MPs (green) (original magnification, ϫ40; resolution 1 m). These images are representative of 3 experiments. D, Preincubation of plaque MPs with annexin V ICAM-1 mRNA upregulation and that plaque MPs harbor measurable amounts of ICAM-1. As tagging MP ICAM-1 leads to the recovery of tagged ICAM-1 on endothelial cells, we hypothesized that ICAM-1 might be transferred from plaque MPs to endothelial membranes as the molecular link between exposure to MPs and increased monocyte adhesion. Such a transfer of protein from MPs to cells has been previously reported for instance for CXCR4 or CCR5. [25] [26] [27] Two types of interactions could contribute to this effect: docking of MPs on the endothelial surface involving a ligand-receptor interaction or fusion of their respective membranes. 20 Several findings support the interpretation that plaque MPs fuse with endothelial cell membranes: (1) high expression levels of fusogenic phospholipid phosphatidylserine on MPs, as attested to by intense annexin V labeling of plaque MPs 4 ; (2) the inhibitory effect of annexin V on ICAM-1 endothelial levels following exposure to MPs; (3) the delivery of a fluorescent dye contained in MPs to the endothelial cell cytoplasm; and (4) the transfer of ICAM-1 from MPs to smooth areas of the endothelial cell surface, as attested by electron microscopy data. Unlike the transfer of tissue factor from in vitro-generated leukocyte MPs to activated platelets, 20 the present study shows that the interaction between plaque MPs and nonactivated endothelial cells does not involve P-selectin and PSGL-1, but we cannot rule out the possibility that other ligand/receptor complexes could be involved. Furthermore, the increase in ICAM-1 levels observed in COS-7 cells, a cell line known not to express ICAM-1, 23 following MP exposure argues against the contribution of specific endothelial docking receptors and strongly favors the membrane fusion hypothesis. Interestingly, the effect of MPs on endothelial ICAM-1 appears to be specific for MPs isolated from human plaque, for an equivalent concentration of MPs isolated from the blood of the same patients did not affect endothelial ICAM-1. Previous work from our group demonstrated that plaque MPs were of different cellular origins than their circulating counterparts and originated mostly from leukocytes. 4 The cellular origin of plaque MPs harboring ICAM-1 remains unclear, but leukocyte-derived or endothelial MPs present in human plaques could harbor ICAM-1 expressed by cells they stem from. 28 Furthermore, we observed that MP-borne ICAM-1 was functionally integrated in target cell membranes. This was associated with an augmented adhesion of U937 monocytes observed both in vitro and ex vivo and a stimulation of transendothelial migration of PMN cells. Anti-ICAM-1 and anti-LFA-1 neutralizing antibodies inhibited U937 cell accumulation, thus demonstrating the contribution of ICAM-1 to this process. Interestingly, plaque MPs from symptomatic patients induced greater monocytic cell adhesion and transmigration than MPs from asymptomatic patients, suggesting a functional difference between these MPs. Although not statistically significant, the apparent greater abundance of phosphatidylserine 4 and of ICAM-1 (this study) in MPs isolated from symptomatic patients could contribute to an increased fusion and transfer of microparticle ICAM-1 to endothelial membrane, leading to a more robust functional effect than that of MPs from asymptomatic patients. However, the present study does not rule out the possibility that another adhesion mechanism could contribute the greater adhesion of monocyte to endothelial cells exposed to MP from symptomatic patients.
Several leukocyte adhesion molecules, including ICAM-1, VCAM-1 and E-selectin, are expressed on vascular endothelial cells in human atherosclerotic plaques. 2 Furthermore, several studies have demonstrated the major implication of ICAM-1 in atherosclerosis through the regulation of monocyte recruitment into atherosclerosis-prone areas. 2 Indeed, ICAM-1 expression is elevated in atherosclerosis-prone aortas. Treatment of Apoe Ϫ/Ϫ mice with anti-ICAM-1 antibodies reduced by 70% macrophage short-term homing into atherosclerotic lesions. 29 In addition, the absence of ICAM-1, CD18 (the ␤-subunit of LFA-1), or both reduced aortic lesion size, suggesting that ICAM-1 together with CD18 participates in the regulation of monocyte homing. 30 Together with the data presented here, these findings support the concept that plaque MPs, which accumulate in atherosclerotic lesions, may favor their development by enhancing the adhesion of monocytes and their transendothelial migration. However, the extent to which plaque MPs contribute to increased endothelial ICAM-1 expression in atherosclerotic lesions remains presently unknown as no general mechanism for MP formation has been demonstrated yet, thus precluding to the design of murine models of atherosclerosis where the formation of plaque MPs could be specifically prevented. Despite this limitation, the concomitant presence of MPs bearing ICAM-1 together with microvascular endothelial cells in advanced lesions let us speculate that plaque MPs could contribute in vivo to the increased ICAM-1 expression observed in atherosclerotic plaque. Indeed, given the existence within the plaque of abnormal microvessels characterized by disorganized branching and immature endothelial tubes with "leaky" imperfect linings, plaque MPs may diffuse within blood stream and thus transfer ICAM-1 to the endothelial cell surface in a "paracrine" manner. 31 It should be highlighted that experiments of the present study were performed with MP concentrations lower than the estimated averaged MP abundance in lesions. 4 Alternatively, given the high concentration in MPs in the plaque (200-fold more concentrated than in the plasma from the same patients 4 ), plaque MPs could increase systemic endothelial inflammation at the time of plaque rupture. They could also directly bind to Mac/LFA complexes in the circulation, therefore preventing leukocyte tethering and binding. However, both these potential effects in the circulation would likely be blunted by the high thrombogenic activity of plaque MPs. 4, 32 In conclusion, our results demonstrate that MPs isolated from human atherosclerotic plaques transfer ICAM-1 onto nonactivated endothelial cells to facilitate monocyte adhesion and transendothelial migration. Therefore, accumulation of MPs in atherosclerotic lesions may contribute to atherosclerotic plaque progression by stimulating the recruitment of inflammatory cells in the lesion.
